EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMI
Tweet Content
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
Show on Archive Page
On
Display in Search Results
On
PDQ
Off